This company has been marked as potentially delisted and may not be actively trading.

Exact Sciences (EXAS) Stock Forecast & Price Target

Get the Latest News and Ratings for EXAS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Exact Sciences and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

EXAS Analyst Ratings Over Time

Type	Current Forecast 5/5/25 to 5/5/26	1 Month Ago 4/5/25 to 4/5/26	3 Months Ago 2/4/25 to 2/4/26	1 Year Ago 5/5/24 to 5/5/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	0 Buy rating(s)	0 Buy rating(s)	2 Buy rating(s)	19 Buy rating(s)
Hold	21 Hold rating(s)	21 Hold rating(s)	21 Hold rating(s)	2 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$92.13	$92.13	$89.56	$70.90
Forecasted Upside	-12.19% Downside	-12.19% Downside	-12.43% Downside	32.95% Upside
Consensus Rating	Reduce	Reduce	Hold	Moderate Buy

EXAS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

EXAS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Exact Sciences Stock vs. The Competition

Type	Exact Sciences	Medical Companies	S&P 500
Consensus Rating Score	1.95	2.30	2.52
Consensus Rating	Reduce	Hold	Moderate Buy
Predicted Upside	-12.19% Downside	892.00% Upside	14.78% Upside
News Sentiment Rating	Neutral News See Recent EXAS News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
3/24/2026	BTIG Research 2 of 5 stars	Mark Massaro 1 of 5 stars	Reiterated Rating	Neutral
1/30/2026	Zacks Research Not Rated		Downgrade	Strong-Buy ➝ Hold
1/22/2026	Weiss Ratings Not Rated		Reiterated Rating	Sell (D-)
1/20/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Anthony Petrone Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform ➝ Neutral	$85.00 ➝ $105.00	+2.51%
1/5/2026	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Vijay Kumar Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Outperform ➝ In-Line	$105.00	+3.20%
11/28/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Daniel Arias Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$80.00 ➝ $105.00	+3.61%
11/25/2025	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Hold
11/25/2025	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kyle Mikson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$85.00 ➝ $105.00	+3.95%
11/24/2025	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Westenberg Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Overweight ➝ Hold	$105.00	+3.97%
11/24/2025	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Bruce D. Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Hold
Get the Latest News and Ratings for EXAS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter.
11/24/2025	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tycho Peterson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$90.00 ➝ $105.00	+4.06%
11/21/2025	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Bill Bonello Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$105.00	+3.97%
11/20/2025	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Luke Sergott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$77.00 ➝ $105.00	+4.30%
11/20/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brandon Couillard Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$85.00 ➝ $105.00	+4.30%
11/20/2025	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andrew Brackmann Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
11/20/2025	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Strong-Buy ➝ Hold
11/20/2025	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Hold
11/20/2025	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Subbu Nambi Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
11/20/2025	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Catherine Ramsey Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$105.00	+3.95%
11/20/2025	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Strong-Buy ➝ Hold
8/7/2025	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Dan Leonard Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$61.00 ➝ $53.00	+28.28%
8/7/2025	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Conor McNamara Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Sector Perform	$54.00 ➝ $46.00	+9.79%
2/24/2025	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Sung Ji Nam Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Sector Outperform	$70.00 ➝ $73.00	+48.92%
2/20/2025	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Derik De Bruin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$72.00 ➝ $65.00	+28.76%
11/6/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$75.00 ➝ $65.00	+25.29%
10/30/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Outperform	$75.00 ➝ $90.00	+26.26%
9/26/2024	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Market Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 04:30 PM ET.

EXAS Forecast - Frequently Asked Questions

: According to the research reports of 22 Wall Street equities research analysts, the average twelve-month stock price forecast for Exact Sciences is $92.13, with a high forecast of $105.00 and a low forecast of $46.00.
: 22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last year. There is currently 1 sell rating and 21 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "reduce" EXAS shares.
: According to analysts, Exact Sciences's stock has a predicted downside of -12.19% based on their 12-month stock forecasts.
: Exact Sciences has been rated by research analysts at BTIG Research in the past 90 days.
: Analysts like Exact Sciences less than other "medical" companies. The consensus rating for Exact Sciences is Reduce while the average consensus rating for "medical" companies is Hold. Learn more on how EXAS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Exact Sciences Recommendations

This page (NASDAQ:EXAS) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.